medric medric
잠시만 기다려 주세요. 로딩중입니다.

진행성 결장직장암에서 Oxaliplatin, 5-Fluorouracil, Leucovorin을 병용한 화학요법(FOLFOX 3)의 전이 병소에 따른 반응률의 차이

Differences of Response Rates according to Metastatic Sites after Oxaliplatin, 5- Fluorouracil, and Leucovorin Combination Chemotherapy (FOLFOX 3) in Advanced Colorectal Cancer

대한대장항문학회지 2005년 21권 1호 p.42 ~ 47
이승현 ( Lee Seung-Hyun ) - 고신대학교 의과대학 외과학교실

안병권 ( Ahn Byung-Kwon ) - 고신대학교 의과대학 외과학교실
백승언 ( Baek Sung-Uhn ) - 고신대학교 의과대학 외과학교실


Purpose: Oxaliplatin is a recently developed active agent in colorectal cancer. Clinical observations have demonstrated synergistic effects of oxaliplatin with 5-fluorouracil (5- FU) and leucovorin (LV), even in 5-FU-resistant colorectal cancer. The purpose of this study was to determine response rates according to clinical factors after oxaliplatin, 5-FU and LV combination chemotherapy (FOLFOX 3) in metastatic colorectal cancer.

Methods: We reviewed 44 patients who had received FOLFOX 3 from Jan. 2000 to Dec. 2002. The combination chemotherapy consisted of oxaliplatin (85 mg/m2 on day 1) as a 2~6 hour infusion followed by continuous infusion of 5-FU (1500 mg/m2 on day 1, 2), concurrently with LV (45 mg on day 1, 2) as a 2 hour infusion. Cycles were repeated by 2-week intervals. We compared the response rates according to clinical factors such as primary sites, cycle, tumor differentiation, metastatic sites, serum CEA, and previous chemotherapy.

Results: Of the 44 patients who had received the combination chemotherapy with oxaliplatin, 5-FU, and LV, 19 cases were male, 25 cases were female. The median age was 50.7 years. The primary tumor sites were colon in 21 cases (47.7%), and rectum in 23 cases (52.3%). The metastatic sites were liver in 27 cases (61.4%), lung in 9 (20.5%), pelvis in 3, lymph node in 5, and peritoneum in 1. Thirty- five patients had received the combination chemotherapy as first line. Complete response was observed in 3 cases (6.8%). Partial response was in 7 cases (15.9%), stable disease status in 15 cases (34.1%), progressive disease status in 19 cases (43.2%), respectively. There were a no significant differences in response rates according to primary sites, tumor differentiation, serum CEA, and previous chemotherapy. However, with the metastatic sites, there were significant differences in response rates. Response rates were higher in lung (5/9), lymph node (3/4) metastases than any other metastatic sites (P<0.01).

Conclusions: The objective response rate of FOLFOX 3 was 22.7% in metastatic colorectal cancers. The only significant clinical factor was metastatic sites. The lung and lymph node metastases showed better response than metastatses to liver, pelvis, and peritoneum. To evaluate the differences of response rates according to metastatic sites, we need further study.


Colorectal cancer;Chemotherapy;Oxaliplatin
원문 및 링크아웃 정보
등재저널 정보